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Abstract 
Background: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which 
has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR 
inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond 
to EGFRicombination therapies, there is a need to develop more reliable molecular signatures to 
better predict response. Here we address the challenge of adapting a gene expression signature 
predictive of RAS pathway activation, created using fresh frozen (FF) tissues, for use with more 
widely available formalinfixed paraffin-embedded (FFPE) tissues. Methods: In this study, we 
evaluated the translation of an 18-gene RAS pathway signature score from FF to FFPE in 54 CRC 
cases, using a head-to- head comparison of five technology platforms. FFPE-based technologies 
included the Affymetrix Gene Chip (Affy), NanoString nCounter™ (NanoS),Illumina whole 
genome RNASeq (RNA-Acc), Illumina targeted RNASeq (t-RNA), and Illuminastranded Total 
RNA-rRNA- depletion (rRNA). 
Results: Using Affy_FF as the “gold” standard, initial analysis of the 18-gene RAS scores on all 
54samples shows varying pairwise Spearman correlations, with (1) Affy_FFPE (r= 0.233, p = 
0.090); (2)NanoS_FFPE (r= 0.608, p &lt; 0.0001); (3) RNA-Acc_FFPE (r= 0.175, p = 0.21); (4) 
t-RNA_FFPE (r=−0.237, p = 0.085); (5) and t-RNA (r= −0.012, p = 0.93). These results suggest 
that only NanoString has successful FF to FFPE translation. The subsequentremoval of identified 
“problematic” samples (n= 15) and genes (n= 2) further improves the correlations of Affy_FF with 
three of the five technologies: Affy_FFPE (r= 0.672, p &lt; 0.0001); NanoS_FFPE (r= 0.738, p 
&lt; 0.0001); and RNA-Acc_FFPE (r= 0.483, p = 0.002). 
Conclusions: Of the five technology platforms tested, Nano String technology provides a more 
faithful translation of the RAS pathway gene expression signature from FF to FFPE than the 
Affymetrix GeneChip and multiple RNASeq technologies. Moreover, Nano String was the most 
forgiving technology in the analysis of samples with presumably poor RNA quality. Using this 
approach, the RAS signature score may now be reasonably applied to FFPE clinical samples. 
 
